Axo Longevity Raises $5 Million in Seed Funding
Axo Longevity, a London-based company focused on preventive health and longevity, has successfully raised $5 million in a seed funding round. The company offers a membership service that helps individuals understand their bodies through the analysis of over 100 biomarkers, providing a personalized health plan and coaching for €490 per year.
Investors and Leadership
The funding round saw participation from a diverse group of investors, including 51 Ventures, Cistern Capital, Daniel Kulle, Everywhere Ventures, Izou Partners, Jorge Planas, LifeX Ventures, MS, AD Ventures, NIAN Sports and Entertainment, and UNQ. Notably, there was no single lead investor in this round.
Axo Longevity was founded by Andrew McCarthy, who serves as the CEO, alongside co-founders Sergio Tang-Sanchez, the Chief Product & Growth Officer, and Octavia Seymour.
Strategic Use of Funds
While the company has not disclosed specific plans for the newly acquired funds, it is expected that the capital will be used to enhance the company's product offerings and expand its market reach. Given the nature of Axo Longevity’s service, investments may likely focus on further developing its health analysis technology and expanding its customer base.
Conclusion
With this new injection of capital, Axo Longevity is well-positioned to continue its mission of providing personalized health insights and preventive care strategies. As the demand for personalized health solutions grows, the company is likely to play a significant role in the evolving landscape of health technology.